Case Report: : A Novel Fusion in a Patient With Gastric Cancer.

Gastric cancer is one of the most common cancers, while the current treatment options for gastric cancer are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of gastric cancer. Different gene rearrangements of anaplastic lymphocyte kinase () have been reported in several types of cancer, especially in NSCLC. The first-generation tyrosine kinase inhibitor (TKI) crizotinib, second-generation (ceritinib, alectinib, and brigatinib) and third-generation (lorlatinib) -TKIs have been widely used for NSCLC patients with rearrangement. However, little was reported about mutation in gastric cancer (GC). Here we identified a novel form of fusion, a case of GC with fusion, and this is the first report of fusion in gastric cancer.